Additional file 2 of Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction

Additional file 2: Supplementary Table 1. The NES values of KEGG pathways that significantly upregulated or downregulated in highly versus lowly TASL groups in more than five cancer types (|NES| ≥ 1.0, P<0.05, FDR<0.25). Supplementary Table 2. Correlation of TASL expression with immune infiltration signatures in 20 cancer types. Supplementary Table 3. ROC curves analysis of TASL, PDL1, PD1, CTLA4 expression, TMB, MSI, and glycolytic activity with immune score and TIL in 20 cancer types. Supplementary Table 4. Correlations of TASL expression with Immune checkpoints, TMB and MSI in 20 cancer types.Supplementary Table 5. Abbreviations, full names and sample sizes for 33 cancer types from the TCGA and GTEx databases. Supplementary Table 6. The original data (E_ normalized values) of TASL expression from GEO datasets used in Figure 6D. Supplementary Table 7. List of datasets from GEO, CGGA, and the article of Miao D, et al. involved in this study. Supplementary Table 8. List of gene sets.